Breaking News Instant updates and real-time market news.

AVXL

Anavex

$4.35

0.11 (2.59%)

10:01
11/05/17
11/05
10:01
11/05/17
10:01

Anavex presents new data of Alzheimer's treatment ANAVEX2-73

Anavex presented new clinical pharmacokinetic and pharmacodynamic data for ANAVEX2-73 in a late-breaking oral presentation at the 2017 Clinical Trials on Alzheimer's Disease Meeting. Data presented include new results from the Phase 1 study, the Phase 2a study, and data from the first year of the Phase 2a long-term extension study. At 109 weeks and halfway into the long-term extension Phase 2a study ANAVEX2-73-003, data from the cohort of patients with the highest ANAVEX2-73 concentrations point toward the continued ability of the medication to stop the decline in the exploratory secondary endpoints cognition and function. At 57 weeks, this cohort had demonstrated improvement of the measures MMSE and ADCS-ADL compared to baseline. For the primary endpoint, ANAVEX2-73 demonstrated continued favorable safety and tolerability through 109 weeks. Additionally, clinical data from 54 subjects from the Phase 1 and the Phase 2a trials were analyzed including using formal concept analysis, non-linear mixed effect modeling and non-compartmental analysis methods. This data provide support to proceed with the clinical development of ANAVEX2-73 for Alzheimer's disease in a focused Phase 2/3 study using the precision medicine paradigm, including DNA whole exome, RNA expression and gut microbiome characterization. Further clinical studies in other indications, such as Rett syndrome and Parkinson's disease are under development utilizing the translational potential of precision medicine approach of ANAVEX2-73. ANAVEX2-73 is a novel, orally available sigma-1 receptor agonist. Sigma-1 receptor, an emerging therapeutic target in Alzheimer's disease and other central nervous system disorders, has been shown to reduce cellular stress and regulate neuroplasticity and cellular homeostasis. The Company previously reported that the Phase 2a trial successfully achieved both primary and secondary endpoints.

AVXL Anavex
$4.35

0.11 (2.59%)

11/28/16
MAXM
11/28/16
NO CHANGE
Target $15
MAXM
Buy
Anavex may be targeting 'ideal approach' to Alzheimer's disease, says Maxim
After Eli Lilly's (LLY) solanezumab failed its third Phase 3 study in early-stage Alzheimer's disease, Maxim analyst Jason McCarthy noted that Anavex's (AVXL) 2-73 targets the disease "more broadly upstream" to restore proper CNS cell function and has shown "promising early data." While too soon to draw any firm conclusions, given the lessons learned from failures in pursuit of other avenues, Anavex "may be on the right track" by looking upstream, said McCarthy, who keeps a Buy rating and $15 price target on the stock.
02/07/17
NBLE
02/07/17
INITIATION
Target $16
NBLE
Buy
Anavex initiated with a Buy at Noble Financial
Noble Financial initiated Anavex with a Buy and a $16 price target.
02/07/17
NBLE
02/07/17
INITIATION
Target $16
NBLE
Anavex initiated with a Buy at Noble Financial
Noble Financial analyst Kumaraguru Raja initiated Anavex with a Buy and a $16 price target. The lead product candidate, ANAVEX 2-73, is on path for a Phase 2/3 in Alzheimer's disease and a Phase 2 study in Rett's Syndrome. In previous trials, ANAVEX 2-73 has exhibited a high affinity and selection to sigma-1 receptors, and has shown synergistic action with other receptors, such as Muscarinic and N-methyl-D-aspartate in clinical trials. The drug has also displayed a favorable side effect profile, which can be beneficial to patients and advantageous when compared to current treatments. Anavex has received a grant from the International Rett Syndrome Foundation for at least $600,000, based on promising animal data. This grant is expected to cover most of the cost of the planned Phase 2 clinical trial of ANAVEX 2-73 in Rett syndrome.

TODAY'S FREE FLY STORIES

ZSAN

Zosano Pharma

$0.47

0.0164 (3.64%)

10:55
01/23/18
01/23
10:55
01/23/18
10:55
Conference/Events
Zosano Pharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

OSTK

Overstock.com

$77.40

-0.25 (-0.32%)

10:50
01/23/18
01/23
10:50
01/23/18
10:50
Periodicals
Overstock ICO promotion 'false and misleading,' Medium contributor says »

A contributor to Medium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip.com

$46.14

-0.71 (-1.52%)

10:50
01/23/18
01/23
10:50
01/23/18
10:50
Options
Short-term put buyers in Ctrip as shares stumble »

Short-term put buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBLN

Obalon Therapeutics

$5.19

-0.05 (-0.95%)

10:46
01/23/18
01/23
10:46
01/23/18
10:46
Hot Stocks
Obalon Therapeutics terminates stock offering after whistleblower allegations »

Obalon Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

TFX

Teleflex

$274.20

-0.55 (-0.20%)

10:44
01/23/18
01/23
10:44
01/23/18
10:44
Conference/Events
Leerink medical devices analysts hold an analyst/industry conference call »

Medical Devices Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

  • 28

    Feb

  • 01

    Mar

TWTR

Twitter

$22.73

-0.5928 (-2.54%)

10:42
01/23/18
01/23
10:42
01/23/18
10:42
Recommendations
Twitter analyst commentary  »

Twitter data points to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

ILG

ILG

$29.45

-0.03 (-0.10%)

10:40
01/23/18
01/23
10:40
01/23/18
10:40
Options
Repeat interest in ILG Mar 30 calls »

Repeat interest in ILG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:35
01/23/18
01/23
10:35
01/23/18
10:35
Conference/Events
Morgan Stanley technology analyst holds an analyst/industry conference call »

Technology/Hardware…

ABEO

Abeona Therapeutics

$14.85

0.25 (1.71%)

, JKHY

Jack Henry

$125.32

0.17 (0.14%)

10:31
01/23/18
01/23
10:31
01/23/18
10:31
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

ABEO

Abeona Therapeutics

$14.85

0.25 (1.71%)

JKHY

Jack Henry

$125.32

0.17 (0.14%)

WWD

Woodward

$81.02

0.52 (0.65%)

NAV

Navistar

$44.96

0.21 (0.47%)

GBT

Global Blood Therapeutics

$56.35

2.4 (4.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

NFLX

Netflix

$227.58

7.12 (3.23%)

, GPRO

GoPro

$6.30

0.01 (0.16%)

10:31
01/23/18
01/23
10:31
01/23/18
10:31
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

NFLX

Netflix

$227.58

7.12 (3.23%)

GPRO

GoPro

$6.30

0.01 (0.16%)

W

Wayfair

$88.60

-2.04 (-2.25%)

FTNT

Fortinet

$45.85

-0.16 (-0.35%)

S

Sprint

$5.23

-0.091 (-1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 01

    Feb

  • 02

    Feb

  • 05

    Feb

  • 22

    Feb

DG

Dollar General

$103.69

1.424 (1.39%)

, DKS

Dick's Sporting

$34.91

0.29 (0.84%)

10:31
01/23/18
01/23
10:31
01/23/18
10:31
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

DG

Dollar General

$103.69

1.424 (1.39%)

DKS

Dick's Sporting

$34.91

0.29 (0.84%)

CAT

Caterpillar

$170.43

-0.46 (-0.27%)

RMD

ResMed

$101.77

14.26 (16.30%)

HPE

HP Enterprise

$16.37

0.315 (1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

SBUX

Starbucks

$61.41

0.15 (0.24%)

10:30
01/23/18
01/23
10:30
01/23/18
10:30
Options
Starbucks calls drawing interest ahead of earnings »

Starbucks calls drawing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

KMB

Kimberly-Clark

$117.35

0.4358 (0.37%)

10:29
01/23/18
01/23
10:29
01/23/18
10:29
Hot Stocks
Breaking Hot Stocks news story on Kimberly-Clark »

Kimberly-Clark:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

KMI

Kinder Morgan

$19.45

-0.18 (-0.92%)

10:28
01/23/18
01/23
10:28
01/23/18
10:28
Hot Stocks
Kinder Morgan begins operations of Utopia Pipeline system »

Kinder Morgan announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$117.26

0.35 (0.30%)

10:27
01/23/18
01/23
10:27
01/23/18
10:27
Hot Stocks
Breaking Hot Stocks news story on Kimberly-Clark »

Kimberly-Clark: China…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

PFIE

Profire Energy

$2.01

0.03 (1.52%)

10:26
01/23/18
01/23
10:26
01/23/18
10:26
Conference/Events
Profire Energy management to meet with Lake Street »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

NFLX

Netflix

$227.58

7.12 (3.23%)

10:25
01/23/18
01/23
10:25
01/23/18
10:25
Conference/Events
Netflix management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

MLHR

Herman Miller

$40.95

0.4 (0.99%)

10:25
01/23/18
01/23
10:25
01/23/18
10:25
Conference/Events
Herman Miller management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 30

    Jan

  • 31

    Jan

10:25
01/23/18
01/23
10:25
01/23/18
10:25
Conference/Events
RBC Capital software analysts hold an analyst/industry conference call »

Software Analysts…

RARE

Ultragenyx

$53.39

4.23 (8.60%)

10:25
01/23/18
01/23
10:25
01/23/18
10:25
Conference/Events
Ultragenyx participates in a conference call with JPMorgan »

Investor conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 17

    Apr

  • 24

    Jan

LLEX

Lilis Energy

$4.86

-0.14 (-2.80%)

10:24
01/23/18
01/23
10:24
01/23/18
10:24
Conference/Events
Lilis Energy management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 31

    Jan

EBAY

eBay

$39.58

1.15 (2.99%)

, GOOG

Alphabet

$1,155.81

18.3 (1.61%)

10:21
01/23/18
01/23
10:21
01/23/18
10:21
Periodicals
eBay CEO says shoppers are shifting to voice technology, CNBC reports »

eBay (EBAY) CEO Devin…

EBAY

eBay

$39.58

1.15 (2.99%)

GOOG

Alphabet

$1,155.81

18.3 (1.61%)

GOOGL

Alphabet Class A

$1,164.16

20.66 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

CMD

Cantel Medical

$112.00

0.7 (0.63%)

10:21
01/23/18
01/23
10:21
01/23/18
10:21
Conference/Events
Cantel Medical management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 31

    Jan

KMB

Kimberly-Clark

$116.87

-0.04 (-0.03%)

10:20
01/23/18
01/23
10:20
01/23/18
10:20
Hot Stocks
Kimberly-Clark sees 2H18 EPS higher than 1H18 »

On its Q4 earnings call,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

10:20
01/23/18
01/23
10:20
01/23/18
10:20
General news
Nasdaq leads major averages as Netflix jumps after earnings »

Stock futures were little…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.